Overview

Study of Tislelizumab for Locally Advanced or Oligometastatic Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy ± Anlotinib

Status:
Recruiting

Trial end date:
2024-02-01

Target enrollment:

Participant gender:

Summary

The phase II Study is to explore the efficacy and safety of Tislelizumab as consolidation therapy in patients with locally advanced or Oligometastatic non-small cell lung cancer who have not progressed following neoadjuvant chemotherapy plus Tislelizumab ± Bevacizumab and definitive concurrent chemoradiation therapy ± Anlotinib.

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Bevacizumab